<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03109600</url>
  </required_header>
  <id_info>
    <org_study_id>Typhoid 0116</org_study_id>
    <nct_id>NCT03109600</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)</brief_title>
  <official_title>A Randomized, Observer Blinded, Comparative, Phase I Safety Study in Two Age De-escalating Cohorts to Assess the Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine (Bio Farma) in Adults and Children (Phase I)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT Bio Farma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT Bio Farma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the safety of Vi-DT vaccine in adults and children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To describe the safety of this vaccine following first and second dose immunization.

      To assess preliminary information of immunogenicity following Vi-DT vaccine immunization.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 18, 2017</start_date>
  <completion_date type="Actual">February 19, 2018</completion_date>
  <primary_completion_date type="Actual">September 28, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local reaction and systemic event after vaccination</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of subjects with at least one immediate reaction (local reaction or systemic event) after vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events after vaccination</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of subjects with at least one of these adverse events, solicited or not, within 24 h, 48h, 72h and 28 days after each vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events after vaccination</measure>
    <time_frame>28 days</time_frame>
    <description>Number and percentage of subjects with serious adverse event from inclusion until 28 day after vaccination and up to 6 months after the last vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Routine laboratory evaluation that probably related to the vaccination.</measure>
    <time_frame>7 days</time_frame>
    <description>Deviation from routine blood laboratory, kidney and liver function laboratory evaluation that probably related to the vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary assessment of immunogenicity of typhoid conjugated vaccine (Vi-DT)</measure>
    <time_frame>28 days</time_frame>
    <description>Percentage of subjects with &gt; 4 times increasing antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titers (GMT) following immunization</measure>
    <time_frame>28 days</time_frame>
    <description>Geometric Mean Titers (GMT) 28 days following immunization</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>Vi-DT (Bio Farma)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 dose of 0.5 ml of Vi-DT Conjugated typhoid vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vi polysaccharide vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of 0.5 ml Vi polysaccharide vaccine + 1 dose of Influenzae Vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vi-DT (Bio Farma) ~ Children</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 dose of 0.5 ml of Vi-DT Conjugated typhoid vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vi polysaccharide vaccine ~ Children</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 dose of 0.5 ml Vi polysaccharide vaccine + 1 dose of Pneumococcal Conjugate Vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vi-DT (Bio Farma)</intervention_name>
    <description>Typhoid Conjugate Vaccine</description>
    <arm_group_label>Vi-DT (Bio Farma)</arm_group_label>
    <arm_group_label>Vi-DT (Bio Farma) ~ Children</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vi polysaccharide vaccine</intervention_name>
    <description>Vi polysaccharide vaccine</description>
    <arm_group_label>Vi polysaccharide vaccine</arm_group_label>
    <arm_group_label>Vi polysaccharide vaccine ~ Children</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Influenzae vaccine</intervention_name>
    <description>1 dose of Influenzae vaccine</description>
    <arm_group_label>Vi polysaccharide vaccine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumococcal conjugate vaccine</intervention_name>
    <description>1 dose of Pneumococcal conjugate Vaccine</description>
    <arm_group_label>Vi polysaccharide vaccine ~ Children</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy

          2. Subjects/Parents have been informed properly regarding the study and signed the
             informed consent form

          3. Subject/Parents will commit to comply with the instructions of the investigator and
             the schedule of the trial

        Exclusion Criteria:

          1. Subject concomitantly enrolled or scheduled to be enrolled in another trial

          2. Evolving mild, moderate or severe illness, especially infectious diseases or fever
             (axillary temperature ³ 37.5°C )

          3. Known history of allergy to any component of the vaccines

          4. History of uncontrolled coagulopathy or blood disorders contraindicating intramuscular
             injection

          5. Subject who has received in the previous 4 weeks a treatment likely to alter the
             immune response (intravenous immunoglobulins, blood-derived products or long term
             corticotherapy (&gt; 2 weeks).

          6. Any abnormality or chronic disease which according to the investigator might interfere
             with the assessment of the trial objectives

          7. Pregnancy &amp; lactation (Adults)

          8. Individuals who have previously received any vaccines against typhoid fever.

          9. Subjects already immunized with any vaccine within 4 weeks prior and expect to receive
             other vaccines within 60 days following the first dose.

         10. Individuals who have a previously ascertained typhoid fever.

         11. History of alcohol or substance abuse.

         12. Subject planning to move from the study area before the end of study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernie Endyarni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Medicine, University of Indonesia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Puskesmas Jatinegara</name>
      <address>
        <city>Jakarta</city>
        <state>DKI Jaya</state>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jatinegara Primary Health Center</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>March 4, 2018</last_update_submitted>
  <last_update_submitted_qc>March 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

